22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Take care of yourself! In medicine, sometimes the practices that get people in trouble are pretty s...
Read More >
On September 24, Cooley M&A partner, Garth Osterman, moderated a webinar on the current trend in goi...
Read More >
On May 31, 2019, the U.S. District Court for the Northern District of California awarded a $102 mill...
Read More >
Welcome to your weekly update from the Allen & Overy Pensions team, bringing you up to spee?d on the...
Read More >
The Department of Labor just published its increases to the maximum civil penalties that can be asse...
Read More >
As counties and municipalities react to the outbreak of COVID-19, the typical development process is...
Read More >